![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
CETUXIMAB A MONOCLONAL ANTIBODY IN TREATMENT OF CANCER OF HEAD AND NECK: LITERATURE REVIEW
Amanda Raquel Silva Lima, Ana Laura Remédio Zeni Beretta*
ABSTRACT Studies indicate that approximately 500 new cases of head and neck cancer are attended annually in poles of Oncology from São Paulo. Tumors of head and neck correspond to the fifth type of cancer most common in the world, presenting high mortality and morbidity. Considering the increase in the number of people with cancer of head and neck, several drugs have been developed for the treatment, one of these medicines is Cetuximab, humanized monoclonal antibody anti-EGFR class IgG1, which was approved by the FDA in March of 2006 for the treatment of unresectable squamous head and neck tumors. The present study aimed to gather the most recent data on the treatment of head and necks tumors with monoclonal antibody Cetuximab. The MEDLINE data base used was – Bireme, National Librayof Medicine (PubMed), Scientific Eletronic LibrayOnline (SciElo), and comprehensive literatures in the subject. The literature review suggests that introduction of Cetuximab in the treatment of head and neck cancer represents advances over conventional treatments. Keywords: Cetuximab. Head and neck cancer. Monoclonal antibody. [Download Article] [Download Certifiate] |